Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system.
about
Antibiotic-free selection in biotherapeutics: now and foreverAntibiotic-free segregational plasmid stabilization in Escherichia coli owing to the knockout of triosephosphate isomerase (tpiA)Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines.Critical design criteria for minimal antibiotic-free plasmid vectors necessary to combine robust RNA Pol II and Pol III-mediated eukaryotic expression with high bacterial production yieldsCoexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine.Vector Design for Improved DNA Vaccine Efficacy, Safety and Production.The future of human DNA vaccinesAnticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response.A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitro.Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.Advances in Non-Viral DNA Vectors for Gene Therapy.New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials.Rational engineering of Escherichia coli strains for plasmid biopharmaceutical manufacturing.Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.Towards effective non-viral gene delivery vector.Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses.Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers.Plasmid DNA fermentation strain and process-specific effects on vector yield, quality, and transgene expression.Antibiotic-free selection in E. coli: new considerations for optimal design and improved productionA 5' Noncoding Exon Containing Engineered Intron Enhances Transgene Expression from Recombinant AAV Vectors in vivo.High-Level Production of Plasmid DNA by Escherichia coli DH5α ΩsacB by Introducing inc Mutations.Effect of plasmid replication deregulation via inc mutations on E. coli proteome & simple flux model analysis.Testing plasmid stability of Escherichia coli using the Continuously Operated Shaken BIOreactor System.De novo creation of MG1655-derived E. coli strains specifically designed for plasmid DNA production.The Antibiotic-free pFAR4 Vector Paired with the Sleeping Beauty Transposon System Mediates Efficient Transgene Delivery in Human Cells.Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.Selection by RNA-RNA Interaction: Maximally Minimized Antibiotic Resistance-Free Plasmids
P2860
Q27028105-CD2CC9EC-0024-47E4-A6BE-416FB6FC93A3Q33552859-445DB11B-FD19-4DDF-BC7B-996ED028C7EEQ33847809-BA231E19-0088-46AE-9BFB-FA5FF067D00DQ34222163-5A39A10F-01D3-4B76-8F54-27996767D07DQ34487821-1B4A37FA-6122-4D16-8B4B-D1339E670E58Q35826665-F06B4FE6-3CE9-43E9-A67F-EFD6338DB265Q36438236-436EE26F-0B3A-40CE-9E57-FB9784B89008Q36821063-4E744686-54CB-4F87-B410-39FA330311B5Q36883864-1A981122-3C8B-40D3-9787-8B3BFAEF8A1FQ37316838-13534C5A-F492-4992-B16F-EA19D846973AQ37398200-1FB73A17-2E13-4543-A44B-E59AE6A84915Q37676243-BC1AEA47-2B75-4573-B6AA-D0DFD5F0AF03Q37924090-02F8F5A1-86A0-4209-B4C8-BE21D3BECF2BQ37931183-0D9F3036-8CE3-4C02-917D-5C86EEBE29C2Q38759383-4CBB8880-36A3-4F0C-9918-66E79694705DQ38830057-8B012116-60D4-42E0-815B-122CB650F6C8Q39181825-DD9F5488-9D2D-4D33-823F-C19E2EC7F23DQ39627661-D1C0DD23-7E95-4875-A8CD-AB35FD4DAC74Q39839158-F8CFA5B4-A4A9-49C0-8CDF-D7A543EC85B7Q39840264-CA172516-9738-435F-959C-C62A8AAB9F7BQ40448692-2A5AEB3B-ADD4-456D-A67A-658DCC6B1265Q43045450-66AEFE42-730F-404D-8429-2A01E69F3E40Q43184002-A9973E86-FA47-4A9B-848A-FD76DF01E641Q47695624-893A9771-5919-40D8-A947-5B9B4E96CCEEQ54330466-52F5F799-FB37-4A3F-B33E-3A991087D7B1Q55365935-FAAF03A9-E3C5-45EC-967C-9793E2A41313Q55432126-CCD7A35F-F928-4FAD-8693-0F129419A971Q58840785-3A3EAEB2-62F8-424F-914A-5F31836B5577
P2860
Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Improved antibiotic-free DNA v ...... ased plasmid selection system.
@en
Improved antibiotic-free DNA v ...... ased plasmid selection system.
@nl
type
label
Improved antibiotic-free DNA v ...... ased plasmid selection system.
@en
Improved antibiotic-free DNA v ...... ased plasmid selection system.
@nl
prefLabel
Improved antibiotic-free DNA v ...... ased plasmid selection system.
@en
Improved antibiotic-free DNA v ...... ased plasmid selection system.
@nl
P2093
P2860
P1433
P1476
Improved antibiotic-free DNA v ...... ased plasmid selection system.
@en
P2093
Aaron E Carnes
Clague P Hodgson
James A Williams
Jeremy Luke
P2860
P304
P356
10.1016/J.VACCINE.2009.06.017
P407
P577
2009-06-24T00:00:00Z